The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 29, 2019
Filed:
Feb. 22, 2012
Applicants:
Bronislava Gedulin, Del Mar, CA (US);
Andrew A. Young, Chapel Hill, NC (US);
Howard E. Greene, Frankfort, MI (US);
Inventors:
Bronislava Gedulin, Del Mar, CA (US);
Andrew A. Young, Chapel Hill, NC (US);
Howard E. Greene, Frankfort, MI (US);
Assignee:
SATIOGEN PHARMACEUTICALS, INC., San Diego, CA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/575 (2006.01); A61K 31/496 (2006.01); A61K 9/00 (2006.01); A61K 9/02 (2006.01); A61K 9/28 (2006.01); A61K 31/155 (2006.01); A61K 31/16 (2006.01); A61K 31/18 (2006.01); A61K 31/19 (2006.01); A61K 31/191 (2006.01); A61K 31/216 (2006.01); A61K 31/38 (2006.01); A61K 31/40 (2006.01); A61K 31/42 (2006.01); A61K 31/452 (2006.01); A61K 31/454 (2006.01); A61K 31/495 (2006.01); A61K 31/4985 (2006.01); A61K 31/4995 (2006.01); A61K 31/513 (2006.01); A61K 31/5377 (2006.01); A61K 31/55 (2006.01); A61K 31/554 (2006.01); A61K 31/655 (2006.01); A61K 31/7042 (2006.01); A61K 45/06 (2006.01); C07C 279/14 (2006.01); C07D 295/13 (2006.01); C07D 401/12 (2006.01); C07D 487/08 (2006.01);
U.S. Cl.
CPC ...
A61K 31/496 (2013.01); A61K 9/0031 (2013.01); A61K 9/02 (2013.01); A61K 9/286 (2013.01); A61K 31/155 (2013.01); A61K 31/16 (2013.01); A61K 31/18 (2013.01); A61K 31/19 (2013.01); A61K 31/191 (2013.01); A61K 31/216 (2013.01); A61K 31/38 (2013.01); A61K 31/40 (2013.01); A61K 31/42 (2013.01); A61K 31/452 (2013.01); A61K 31/454 (2013.01); A61K 31/495 (2013.01); A61K 31/4985 (2013.01); A61K 31/4995 (2013.01); A61K 31/513 (2013.01); A61K 31/5377 (2013.01); A61K 31/55 (2013.01); A61K 31/554 (2013.01); A61K 31/575 (2013.01); A61K 31/655 (2013.01); A61K 31/7042 (2013.01); A61K 45/06 (2013.01); C07C 279/14 (2013.01); C07D 295/13 (2013.01); C07D 401/12 (2013.01); C07D 487/08 (2013.01);
Abstract
Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.